NCT05553873 Evaluation of Inflammatory Markers in ph Negative Myeloproliferative Neoplasms: Impact on Outcome and Response to Therapy. Multicenter Retro-prospective Observational Study. The INFLA-ME (INFLAmmation in Myeloproliferative Disease) Study.
| NCT ID | NCT05553873 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Milano Bicocca |
| Condition | Myeloproliferative Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2022-09-08 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2022-09-08 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to observe inflammatory biomarkers and their trend over the history of the disease in patients suffering from MPN Ph negative; it also wants to identify any correlations between the aforementioned biomarkers and disease outcomes, considering first of all the occurrence of thrombo-haemorrhagic events and the evolution in the accelerated / blast phase of the disease, shedding light on new tools that can potentially guarantee a prompt and better risk stratification
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years at the time of diagnosis of MPN Ph negative * Diagnosis of PV, ET, PMF or post PV and post ET MF, according to current WHO or IWG-MRT criteria (diagnosis since 2000) * Obtaining informed consent Exclusion Criteria: * Life expectancy of less than 6 months * Accelerated phase myelofibrosis or MPN with signs of leukemic evolution
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05553873 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Myeloproliferative Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05553873 currently recruiting?
Yes, NCT05553873 is actively recruiting participants. Contact the research team at elena.elli@libero.it for enrollment information.
Where is the NCT05553873 trial being conducted?
This trial is being conducted at Bari, Italy, Bologna, Italy, Brescia, Italy, Catania, Italy and 7 additional locations.
Who is sponsoring the NCT05553873 clinical trial?
NCT05553873 is sponsored by University of Milano Bicocca. The trial plans to enroll 500 participants.